Listed

Nephros Inc: Form 10-Q for the period ended Mar 31, 2017

Filed with the SEC on May 9, 2017 and accepted by EDGAR at May 9, 2017, 07:32 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2017-01-01 to 2017-03-31$734.0kus-gaap:SalesRevenueNet
Cost of revenue3 months2017-01-01 to 2017-03-31$279.0kus-gaap:CostOfGoodsSold
Gross profit3 months2017-01-01 to 2017-03-31$455.0kus-gaap:GrossProfit
Selling, general and administrative3 months2017-01-01 to 2017-03-31$770.0kus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2017-01-01 to 2017-03-31−$605.0kus-gaap:OperatingIncomeLoss
Interest expense3 months2017-01-01 to 2017-03-31$66.0kus-gaap:InterestExpense
Net income3 months2017-01-01 to 2017-03-31−$680.0kus-gaap:NetIncomeLoss
Diluted EPS3 months2017-01-01 to 2017-03-31−$0.01us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2017-01-01 to 2017-03-31−$659.0kus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash and equivalentsAt period end2017-03-31$803.0kus-gaap:Cash
Current assetsAt period end2017-03-31$1.9mus-gaap:AssetsCurrent
Total assetsAt period end2017-03-31$3.3mus-gaap:Assets
Current liabilitiesAt period end2017-03-31$780.0kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-03-31$1.9mus-gaap:Liabilities
Shareholders' equityAt period end2017-03-31$1.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-17-004892. Last ingested by Listed: Nov 13, 2026, 16:20 ET. Listed shows no prices and gives no investment advice.